JSPR

Jasper Therapeutics is a clinical-stage biotechnology company developing therapies based on targeting CD117 (c-Kit) for hematopoietic stem cell transplant conditioning and cancer treatment. The company's lead product candidate is briquilimab, an antibody designed to clear hematopoietic stem cells from bone marrow to prepare patients for transplantation without the need for toxic chemotherapy or radiation. Jasper's approach aims to make stem cell transplants safer and accessible to more patients, potentially transforming treatment for blood disorders, autoimmune diseases, and cancer. The company is advancing multiple clinical trials evaluating briquilimab in various conditioning applications.